|
Catalyst Biosciences, Inc., a biotechnology company founded in 2003, engages in engineering and developing therapeutic protease products. Catalyst offers Alterase therapeutics for the treatment of hemophilia, inflammation, cardiovascular, metabolic, and angiogenesis-based disorders.
Cell Therapeutics Inc. develops, acquires, and commercializes innovative treatments for cancer,
and is developing a diversified portfolio of oncology products focused
on identifying new, less toxic, and more effective cancer therapies.
Ception Therapeutics, Inc., is an emerging biopharmaceutical company focused on the discovery and development of novel products to address unmet medical needs.
Chroma Therapeutics, Ltd., is a biotechnology company founded to exploit the potential of chromatin biology for cancer drug discovery. The company is focused on the identification of novel anti-cancer agents that combine the efficacy of cytotoxics with the tumor cell selectivity of modern targeted therapeutics. Chroma is developing a pipeline of novel anti-cancer drugs, primarily by exploiting the world-class expertise of its founders in the field of chromatin biology and the development of new molecular cancer therapeutics.
Complete Genomics, Inc. operates as a human genome sequencing company and provides human genome sequencing services for pharmaceutical and biotechnology companies, as well as other medical researchers, to conduct human genome studies for various diagnostic and discovery applications. The company’s services include human DNA sequencing data, data management and analysis, and DNA sequencing of human populations.
Confluent Surgical is a private medical device company pioneering the development of
In-situ-polymerized Biomaterials. These materials have almost universal
applications across minimally invasive surgery because they allow the
safe, simple, and rapid formation of customized implants at the site of
disease. This process can take place rapidly when two aqueous solutions
of molecularly designed synthetic polymers mix together. Confluent's
vision is to address unmet needs in surgery and interventional
procedures using its technology platform of in situ polymerization.
Elusys Therapeutics is a privately-held biopharmaceutical company focused on the development of antibody-based therapies for the treatment of infectious disease. The Company has pioneered the development of a rapid injection, therapeutic antibody, Anthim™, for the treatment of anthrax infection following a biowarfare attack. Anthim has completed a phase I safety study and is a leading candidate for purchase by the U.S. government.
Intercell AG (formerly Iomai Corp.) has developed a method to safely and more effectively deliver vaccines through the use of a skin patch and without any injections.
La Jolla Pharmaceutical Company is a biotechnology company leading the development and marketing
of novel therapeutics for antibody-mediated autoimmune diseases, such as
lupus and antibody-mediated thrombosis.=
LifeCell Corporation develops and markets biologic products for the repair or replacement of
damaged or inadequate tissues. The Company's core preservation
technology produces an acellular tissue matrix, which retains the
essential biochemical and structural components necessary for normal
tissue regeneration.
Light Sciences Oncology, Inc., has developed an innovative, practical, targeted therapy that can destroy previously untreatable tumors. Its therapeutic platform combines the best-in-class light activated drug and novel light generation devices to destroy tumors from the inside out. Phase III clinical trials will soon start to treat patients with the two major cancer killers in the world – hepatoma and metastatic colorectal cancer. Light Sciences Oncology intends to provide physicians with the tools to treat cancer as a non-life threatening chronic disease.
Open Monoclocal Technology (OMT) is an early-stage biotech company, that is building the first platform for generating human monoclonal antibodies using a transgenic rat.
Symphogen A/S is an early-stage, technology-platform company that is developing a method to produce antigen-specific human polyclonal antibody preparations via recombinant or cell culture manufacturing techniques. This would provide a potentially unlimited supply of human polyclonal antibodies against any desired target compound(s) or pathogen(s) – obviating the need to purify immunologically-active, polyclonal antibodies from either human blood or other non-human blood sources.
Rinat Neuroscience was a privately held biotechnology company dedicated to the discovery and commercialization of novel antibody based drugs and drug targets for the major mental and neuro-degenerative diseases. In 2006, Pfizer expanded neuroscience research and acquired Rinat. Rinat is now a part of Pfizer Global Research & Development and is an integral part of Pfizer's biotherapeutic discovery efforts.
Targeted Genetics Corp. is a leader in gene delivery technology and in the development of
therapeutic products based on gene delivery.
|
